about
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicineImmune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors.IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.Impact of host genes and strand selection on miRNA and miRNA* expression.Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia.Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcomeDistinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.Identification of primary MAFB target genes in multiple myeloma.Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma.Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma.Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myelomaThe proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.Long Non-Coding RNAs in Multiple Myeloma.Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.Improved risk stratification in myeloma using a microRNA-based classifier.Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma.Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters
P50
Q26799238-2E61E2DB-BF15-4018-ADDD-AB2B21C49465Q33399624-97E5BB91-A059-41C1-AD3C-7D83FFDDDD79Q33574203-7F94DAE6-C8DB-4DBA-8C06-8CBE2C95C60FQ33755493-D6FBE737-DC28-41AC-89D9-34ABA2A9B5A1Q34016398-5E617CF7-6784-4ADA-B149-F82B8F66E1E1Q34978154-919DDB40-79C3-44DD-BA3A-921DBF16917EQ35131224-371B7AC4-9926-4063-A860-E454259ED2BDQ36413387-119CB55B-3C06-4617-8FEC-F111B6D35680Q36439245-BA55458A-FC02-4144-94BB-B8E08DF1C631Q38395979-EADAB0DE-CA2A-42EF-8179-97FFAC03D31AQ38764048-09D38C60-BFD9-4C0E-8F7E-BCE5DDB18D32Q38766239-D3F648CB-B2A4-428F-AE2A-0BAD90117F52Q38822886-B04B5E5F-F9B5-4A46-893C-5A42986A9689Q38905792-853FB8CB-FC64-4529-9B47-0CD6E6B537C8Q39205798-15700A83-524A-41BB-8B86-4C8AE7F03FF0Q39430844-C26F970C-0D3C-4214-B138-7380A17DC10FQ39616165-87FCC080-D561-4664-A96C-A2FC31D04EB0Q39869539-C78B4C46-F0EE-417C-AF0F-BAA1E11F3B01Q39916085-2148EFAB-6117-4878-9D54-4821DDB97A78Q39923951-385F46F5-5391-4853-87DC-C94BAD6D93F7Q40046832-0EEC9B09-A1C5-42BD-B75B-750DC164825EQ40083717-1A31DDBD-5720-4466-9909-C1F4DE2F26D0Q40195859-31DA76BE-6709-4381-894B-CCC6A1A41DE8Q40220950-5EDB16E9-E025-4229-B9F9-B1ABE8715F10Q40856384-20F70B80-A19E-4913-A06D-46BB73DF6415Q42846656-F26EE866-DA04-4AA4-8B86-A29B793C9561Q44447816-2EECD861-DEFD-48C2-B1E4-C240A53D6DC6Q44774590-AF491FF8-9C5F-48C9-AD8B-477A7A0DA2F4Q45330340-CCBD1B15-CFF9-49E3-90D1-0D5C8A87BC53Q45392132-DD85EC40-86F1-4F80-83CA-57E2C55F1311Q46410066-987CA75D-C1ED-469E-8FBB-3AFF777A6783Q48124218-5AB5D70A-A598-4033-BF70-E96FA6D31276Q51647676-5A78F740-ABE4-40E4-B848-FCDB0E02FF26Q52682394-87977EC2-9915-44DA-85C0-999B18B965DEQ53109542-FC5D40CD-FDEA-4854-B16D-14E34CA4D2D0Q54301591-EE5C2455-9766-4D46-A9EE-E24153536ACDQ54646402-29307CAE-D335-49BB-BAF9-44F756606184Q55082350-35D7216F-C9AE-4371-89F7-402EDB0F55A1Q55438852-E9282B82-09DA-4331-9304-0644712D870AQ56097570-520030D1-57AA-4857-9B1F-F0D55E2BAAC2
P50
description
investigador
@es
researcher
@en
name
Luca Agnelli
@en
Luca Agnelli
@nl
type
label
Luca Agnelli
@en
Luca Agnelli
@nl
prefLabel
Luca Agnelli
@en
Luca Agnelli
@nl
P31
P496
0000-0003-0582-6170